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Abstract
Patients with small intestinal neuroendocrine tumors (SI-NETs) frequently develop spread disease; however, the underlying
molecular mechanisms of disease progression are not known and effective preventive treatment strategies are lacking. Here,
protein expression profiling was performed by HiRIEF-LC-MS in 14 primary SI-NETs from patients with and without liver
metastases detected at the time of surgery and initial treatment. Among differentially expressed proteins, overexpression of
the ubiquitin-like protein NEDD8 was identified in samples from patients with liver metastasis. Further, NEDD8 correlation
analysis indicated co-expression with RBX1, a key component in cullin-RING ubiquitin ligases (CRLs). In vitro inhibition
of neddylation with the therapeutic agent pevonedistat (MLN4924) resulted in a dramatic decrease of proliferation in SI-
NET cell lines. Subsequent mass spectrometry-based proteomics analysis of pevonedistat effects and effects of the
proteasome inhibitor bortezomib revealed stabilization of multiple targets of CRLs including p27, an established tumor
suppressor in SI-NET. Silencing of NEDD8 and RBX1 using siRNA resulted in a stabilization of p27, suggesting that the
cellular levels of NEDD8 and RBX1 affect CRL activity. Inhibition of CRL activity, by either NEDD8/RBX1 silencing or
pevonedistat treatment of cells resulted in induction of apoptosis that could be partially rescued by siRNA-based silencing of
p27. Differential expression of both p27 and NEDD8 was confirmed in a second cohort of SI-NET using
immunohistochemistry. Collectively, these findings suggest a role for CRLs and the ubiquitin proteasome system in
suppression of p27 in SI-NET, and inhibition of neddylation as a putative therapeutic strategy in SI-NET.
Introduction
Small intestinal neuroendocrine tumor (SI-NET) is a rare
disease with an incidence of around 1 per 100,000, but still
the most common small intestinal malignancy [1]. SI-NETs
develop from enterochromaffin cells, are positive for neu-
roendocrine markers, and the diagnosis is based on
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histopathological examination [2]. The patients typically
present with one or more small primary tumors, often
together with mesenteric lymph node metastases, and later
development of distant metastases frequently to the liver.
Although the tumors are commonly slow growing based on
a low Ki-67 proliferation index, the clinical picture suggests
that tumor cell disconnection and spreading occur early in
the tumor development [3].
The primary treatment of SI-NET is surgical. In addition,
the frequent expression of somatostatin receptors in SI-
NETs has led to the development and successful application
of somatostatin analog treatment. Although this treatment
may improve symptoms and also in some patients delay
tumor progression, additional therapeutic strategies need to
be identified and developed for patients with metastatic
disease.
SI-NETs are characterized by a few recurrent genetic
aberrations such as copy number loss of chromosome 18,
which is seen in >70% of the cases [4]. The high frequency
of this event spawned a search for putative tumor supressors
located on chromosome 18 in SI-NET, resulting in the
identification of DCC (deleted in colorectal cancer) as the so
far best candidate [5]. Even though SI-NETs are in general
mutationally quiet, the application of genome-wide
sequencing identified CDKN1B as a recurrently mutated
gene in SI-NET with a frequency of 8% [6]. In addition, a
broad molecular subtyping of SI-NET was recently reported
where genomic, epigenomic, and transcriptomic profiles
were used to suggest three molecular subtypes of SI-NET
with differences in progression-free survival [7]. However,
the molecular background of SI-NET development, specific
oncogenic drivers, and mechanisms of metastatic spread
still remain largely unknown. In addition, no study so far
has integrated proteome-level information in the analysis of
SI-NET from primary tumors.
CDKN1B encodes p27, a bona-fide tumor suppressor that
controls cell cycle entry through inhibition of cyclin/cyclin
dependent kinase (CDK) activity. It has been thoroughly
demonstrated that the CDK inhibitor p27 is regulated pri-
marily by ubiquitination and subsequent proteasomal
degradation [8], and that the ubiquitin E3-ligase responsible
for the ubiquitination is the SCFSkp2 Cullin Ring Ligase
(CRL) complex [9]. The SCFSkp2 complex was later shown
to include Skp1, Cullin-1, Rbx1, and Skp2 as the core
complex components [10]. Increased degradation of p27 in
cancer has also been firmly established beginning with a
seminal study where increased p27-specific proteolytic
activity was coupled to low abundance of p27, which in turn
was demonstrated as a powerful negative prognostic factor
in colorectal cancer [11]. An overwhelming abundance of
reports since then connects overexpression of Skp2 (the F-
box protein that recognize p27) with loss of p27 protein and
poor prognosis in a long list of different cancer types [12].
Importantly, it has been shown that substrate recognition
and activity of CRLs (such as SCFSkp2) is strongly depen-
dent on neddylation of the Cullin subunit [13]. The ned-
dylation process is similar to ubiquitination and includes
E1, E2, and E3 enzymes that catalyze conjugation of target
proteins with the ubiquitin-like protein NEDD8 (neural
precursor cell expressed, developmentally downregulated 8)
[14]. Cullin neddylation results in a conformational change
of the CRL complex, eliminating the binding site for the
CRL inhibitor Cand1 and, at the same time, providing a
more open structure favoring polyubiquitination [15].
Here we performed in-depth proteomics profiling of 14
primary SI-NET tumors with focus on proteome-level
differences between tumors from patients with and without
liver metastasis. This clinical proteomics analysis impli-
cated differences in the ubiquitination machinery, with
higher expression of NEDD8 and RBX1 in tumors from
patients with liver metastasis. To further investigate the
importance of these findings, inhibition of neddylation was
performed in SI-NET cell lines resulting in reduced pro-
liferation and induction of apoptosis. Proteomics profiling
of the effects of neddylation inhibition in two SI-NET cell
lines resulted in identification of multiple upregulated
proteins known to be substrates of CRLs including p27.
Our findings thus suggest deregulation of CRLs as well as
an alternative route for CDKN1B/p27 inactivation in SI-
NET with possible connections to metastatic spread and
therapy.
Results
Proteomics profiling of primary SI-NETs indicate
NEDD8 and RBX1 overexpression in patients with
liver metastases
In order to investigate the proteomic landscape of SI-NET,
and especially to identify proteins connected to disease
progression and metastatic spread, we performed in-depth
proteomics profiling of 14 primary SI-NETs of which 7
presented with liver metastases, while 7 were without any
detectable liver metastasis at the time of surgery (Supple-
mentary Table S1). High-resolution isolectric focusing
liquid chromatography–tandem mass spectrometry (HiR-
IEF-LC-MS)-based proteomics combined with relative
quantification of proteins between samples (iTRAQ-label-
ing) resulted in the identification and quantification of 6775
proteins across all 14 SI-NET samples (Supplementary
Table S2). Unsupervised analysis using principal compo-
nent analysis of the 14 samples revealed no major batch
effects between the 2 separate quantitative proteomics
experiments (2 iTRAQ 8-plex kits), but indicated 2 poten-
tial outliers in the analysis (sample Screen-8 and -12;
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Supplementary Fig. S1a, b). Unsupervised Spearman’s
hierarchical clustering, however, did not indicate the two
samples as outliers. Instead, this clustering resulted in a
separation of samples based on experimental batch and,
more interestingly, on liver metastases (Supplementary
Fig. S1c).
Next, a supervised analysis was performed to identify
protein-level differences between SI-NETs from patients
with and without liver metastases. This analysis resulted in
the identification of 538 differentially expressed proteins (p
< 0.05; Supplementary Table S3). Five proteins showed a
more than twofold difference between groups including
NEDD8, PSMB9, and TFF2 showing higher expression,
and CADM3 and GAP43 showing lower expression in SI-
NETs from patients with liver metastases (Fig. 1a). CADM3
has previously been proposed as a tumor suppressor in
glioma where loss of CADM3 expression is frequently
observed [16]; however, somatic CADM3 mutations and
copy number aberrations seem rare in human cancers
(COSMIC database). Also of potential importance, the
closely related TFF2 family member TFF3 was recently
shown expressed in SI-NETs, and in addition the serum
level of TFF3 was associated with poor survival [17].
However, the previously shown connection between
NEDD8 and cancer through its involvement in regulation of
CRL activity [18] directed our focus and continued inves-
tigations to this protein.
To identify additional proteins with a potential functional
coupling to NEDD8 in SI-NET, we performed a NEDD8
correlation analysis across the 14 samples. Strikingly, one
of the most highly NEDD8 correlating proteins in this
analysis was RBX1, another CRL core complex member
(Fig. 1b and Supplementary Table S4). To further evaluate
the expression of the 538 differentially expressed proteins
across the 14 SI-NET samples, hierarchical clustering was
performed, resulting in two main sample clusters (Fig. 1c).
Six out of seven SI-NETs without liver metastases fell into
the same cluster, whereas the other cluster included all
tumors with liver metastases together with the remaining
case without liver metastases (sample Screen-14).
The differential expression of NEDD8 and RBX1 in SI-
NET together with the potential link to progression
prompted us to investigate these genes further using public
domain data generated in The Cancer Genome Atlas project
(TCGA) [19]. Gene expression data covering 31 different
cancer types (PanCancer dataset) indicated a significant
spread in the expression of NEDD8 both between and
within cancer types (Fig. 1d). SI-NETs are not represented
in the TCGA PanCancer dataset, but pheochromocytoma/
paraganglioma, the only neuroendocrine tumor type inclu-
ded, showed high expression of NEDD8, supporting a role
of this gene in NET. Further, a NEDD8 correlation analysis
revealed that one of the genes with the highest NEDD8
correlation across the different cancer types was RBX1 (Fig.
1e, f). These results indicate a co-regulation of NEDD8 and
RBX1 at the transcriptional level, underscoring the func-
tional association between these proteins and suggesting
that some cancer types rely more on processes that are
dependent on CRL activity for protein degradation.
In summary, our analysis shows differential NEDD8/
RBX1 expression at the protein level in SI-NETs, and a
possible connection between CRL-dependent processes and
progression of SI-NET.
SI-NET cells are sensitive to the neddylation
inhibitor pevonedistat
Based on our proteomics analysis of SI-NETs we speculate
that aberrant neddylation in SI-NETs is of possible impor-
tance for tumor progression and treatment strategies. To
evaluate this hypothesis we used a neddylation inhibitor
(pevonedistat, MLN4924) that targets the NEDD8-
activating enzyme 1 (NAE1) [20]. The most well-studied
targets of neddylation are cullins, core proteins in CRLs,
which require neddylation for activation, and therefore
pevonedistat acts as an indirect inhibitor of CRL activity.
To study the effects of neddylation inhibition, four dif-
ferent NET cell lines (CNDT2 and HC45, both originating
from liver metastasis of SI-NET; BON-1, pancreatic origin;
NCI-H727, bronchial origin) were treated with pevonedistat
at seven different concentrations ranging from 100 to
2000 nM. After 3 days of treatment, decreased proliferation,
as assessed by Bromodeoxyuridine (BrdU) incorporation,
was observed in all four cell lines (Fig. 2a and Supple-
mentary Fig. S2), with the most dramatic effect observed in
the SI-NET cell lines CNDT2 and HC45 (IC50: 149 nM and
322 nM, respectively, Fig. 2a). Previous studies in other
cancer types have shown pevonedistat IC50 values in the
range of 50–1000 nM [20], indicating that at least CNDT2
and HC45 are sensitive to pevonedistat treatment. To fur-
ther evaluate the sensitivity of NET cells in relation to other
cancer cells, we used data generated in the Genomics of
Drug Sensitivity in Cancer (GDSC) project [21]. The GDSC
data contain pevonedistat response measurements for 692
different cancer cell lines with a median pevonedistat IC50
value of 1100 nM (Fig. 2b). Both SI-NET cell lines inves-
tigated here showed an IC50 value well below the GDSC
median, and in particular CNDT2 cells were comparable to
the more sensitive cell lines in the GDSC analysis.
Grouping the pevonedistat sensitivity measurements from
GDSC by cell origin indicated large differences in sensi-
tivity within each tissue type (Fig. 2c). To identify potential
pevonedistat response markers, mRNA profiling data were
downloaded from GDSC and used to perform a differential
expression analysis between the pevonedistat-sensitive and
-resistant GDSC cell lines as indicated in Fig. 2b. This
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analysis indicated that none of the neddylation machinery
components (NAE1, UBA3, UBE2M, RBX1, SENP8) or the
cullins were useful as predictive mRNA level biomarkers
for pevonedistat response (Fig. 2d, NEDD8 itself was not
part of the GDSC data). Instead, the analysis indicated that
epithelial markers (EPCAM, ESRP1, CDH1, and KRT19)
were significantly lower in pevonedistat-sensitive cell lines,
whereas the mesenchymal marker VIM was higher. The
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indication that pevonedistat sensitivity is higher in non-
epithelial cells would support a potential use of pevonedistat
in NET cells as indicated by the relatively low EPCAM
expression in pheochromocytoma/paraganglioma in the
TCGA PanCancer dataset (Fig. 2e). It should be noted
although that pheochromocytoma/paraganglioma is an
imperfect proxy for SI-NETs in this case, as SI-NETs show
varying expression of epithelial markers [22].
Pevonedistat treatment of SI-NET cells results in
stabilization of multiple CRL substrates with tumor
suppressor function including p27
To investigate the specific activity of pevonedistat in SI-
NET cells, we used proteomics profiling of pevonedistat-
treated cells to identify stabilized proteins. Based on the
results from proliferation analyses, CNDT2 and HC45 (both
of SI-NET origin) were selected for further analysis. To
identify protein-level regulation in response to pevonedistat
treatment, CNDT2 and HC45 cells were analyzed by pro-
teomics in biological duplicates as untreated or after treat-
ment with pevonedistat (400 nM) for 3, 6, 12, and 24 h.
HiRIEF-LC-MS proteomics profiling with relative quanti-
fication using TMT isobaric labeling resulted in the iden-
tification and quantification of 10,551 and 11,298 proteins
across all samples in CNDT2 and HC45 experiments,
respectively (Supplementary Tables S5 and S6).
As only duplicate samples were analyzed for each time
point, differential expression analysis was performed based
on a fold change cutoff defined by the quantitative robust-
ness in each cell line separately (Supplementary Fig. S3).
Proteins with consistent up- or downregulation in the two
replicates were included in the further analyses. Increasing
numbers of regulated proteins over time were observed,
with more proteins being upregulated than downregulated
in both cell lines (Fig. 3a). In addition, the response
appeared to be more rapid in CNDT2 cells, which is also
supported by the higher sensitivity to pevonedistat treatment
as discussed above. Our primary interest in the proteomics
analysis of pevonedistat effects was to identify stabilized
proteins, including potential CRL targets in SI-NET cells. In
total, 651 proteins were upregulated 24 h after treatment
with 366 proteins upregulated in CNDT2 and 373 proteins
in HC45, of which 88 proteins were common for both cell
lines (Fig. 3b and Supplementary Table S7). Interestingly, a
closer analysis of these 88 proteins indicated that most of
them were stabilized already 3 h after treatment (Fig. 3c).
Such early effects would indicate posttranscriptional reg-
ulation such as altered degradation, as secondary effects that
rely on transcription would have little time to manifest
themselves at the protein level already 3 h after treatment.
Indeed, a comparison with previously published lists of
candidate CRL substrates [23] revealed a large number of
proteins in common (Fig. 3d), many of which are well-
known substrates of CRLs, as exemplified by NFE2L2/Nrf2
and CDKN1B/p27.
With the hypothesis that CRL overactivation can con-
tribute to the development of cancer through degradation of
tumor suppressor proteins, we investigated whether some of
the stabilized proteins here identified had a previously
known connection to cancer. As part of the catalog of
somatic mutations in cancer (COSMIC), the Cancer Gene
Census is a collection of genes that have been causally
implicated in cancer [24]. The latest version (downloaded
25 October 2018) contains 719 genes, and out of these 719
genes, 43 were identified at the protein level as stabilized
after treatment with pevonedistat in SI-NET cells (Fig. 3e).
Out of these, 22 were associated with a tumor suppressor
role in cancer, including 3 proteins that were stabilized in
both CNDT2 and HC45 cell lines in response to pevone-
distat treatment (CDKN1B/p27, NFE2L2/Nrf2, and SPOP).
Further, 168 of the 651 proteins that were stabilized in
response to pevonedistat were also identified and quantified
in the SI-NET clinical proteomics experiment. For these
proteins, a NEDD8 correlation analysis was performed to
investigate potential functional association in clinical sam-
ples (Fig. 3f). Interestingly, one of the highest correlating
proteins was p27 (Pearson’s corr: 0.57), supporting a
potential functional link between NEDD8 and p27 in clin-
ical samples.
True substrates regulated directly by CRL-dependent
ubiquitination and proteasomal degradation should be sta-
bilized also by inhibition of the proteasome. To further
narrow the list of candidates, we therefore performed an
additional MS-based proteomics experiment where we
treated CNDT2 cells with the protesome inhibitor bortezo-
mib, alone or in combination with pevonedistat. This
experiment resulted in the identification and quantification
of 9434 proteins, with an overlap of 8507 proteins to the
Fig. 1 Proteomics profiling of SI-NET. a Volcano plot of the results
from differential analysis of protein levels between tumors from
patients with/without liver metastasis. Indicated in the plot are proteins
with p-value below 0.05 and more than twofold different expression
between groups. b Density plot showing the distribution of NEDD8
correlations for 6775 proteins quantified in the proteomics analysis.
Indicated in red is RBX1, a core complex member of Cullin-RING
ubiquitin ligases. c Clustering of differentially expressed proteins (p <
0.05) between cases with and without liver metastases. The bar chart
below shows relative protein expression levels from mass spectro-
metry analysis for NEDD8 and RBX1 in individual SI-NETs. The
vertical line indicates the division of samples into two clusters. d
NEDD8 mRNA expression across 31 cancer types in the TCGA
PanCancer dataset. Indicated in the boxplot is pheochromocytoma and
paraganglioma, a neuroendocrine tumor (NET) type. e Density plot
showing the distribution of NEDD8 correlations at mRNA level for
20312 transcripts quantified in the TCGA project. Indicated in red is
RBX1. f Scatterplot showing the expression of NEDD8 and RBX1 in all
9755 samples in the TCGA dataset
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data generated after pevonedistat treatment alone in CNDT2
cells as described above (Fig. 4a and Supplementary Table
S8). In total, bortezomib treatment of CNDT2 cells resulted
in stabilization of 629 proteins (1.5-fold, adjusted p-value <
0.01) out of which 84 were found stabilized also by the
pevonedistat treatment alone, with 38 also stabilized in the
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Fig. 2 SI-NET cells are sensitive to pevonedistat. a Drug sensitivity
analysis by BrdU incorporation in SI-NET cell lines after pevonedistat
treatment to inhibit neddylation. CNDT2 (top) or HC45 (bottom) cells
were treated with pevonedistat for 72 h at different concentrations
before the assay readout. b Density plot showing the distribution of
pevonedistat IC50 values across 692 different cell lines as reported in
the GDSC project. Indicated in the plot are the 10th and 90th per-
centiles used to define cell lines as sensitive or resistant. Also indicated
in the plot are the measured IC50 values for the two SI-NET cell lines.
c Boxplot showing the distribution of pevonedistat IC50 values per
tissue of origin for the cell lines in the GDSC panel. d Vulcano plot
showing the output from a differential expression (DE) analysis
between pevonedistat-sensitive and -resistant cell lines based on
GDSC mRNA data. Indicated in the plot are markers of epithelial
(green) or mesenchymal (red) lineage. Indicated in blue are genes with
known role in CRL-dependent processes. e Epithelial marker EPCAM
mRNA expression across 31 cancer types in the TCGA PanCancer
dataset. Indicated in the boxplot is pheochromocytoma and para-
ganglioma, a neuroendocrine tumor type
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HC45 cells (Fig. 4a, b). Further, our analysis showed that
when combining bortezomib and pevonedistat, a subset of
proteins stabilized by bortezomib treatment alone was even
more stabilized by the combination treatment, strongly
indicating that these proteins are substrates of CRL-
dependent ubiquitination and proteasomal degradation
(Fig. 4c). Out of these proteins, 30 (including p27; Fig. 4d)
were identified as candidate CRL substrates by pevonedistat
treatment alone in CNDT2 cells, including 21 proteins
also stabilized in HC45 cells after pevonedistat treatment
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(Fig. 4e). Several of these proteins are prototype CRL
substrates and four of the proteins including p27
(CDKN1B), p21 (CDKN1A), nrf2 (NFE2L2), and SPOP
are tumor suppressors according to COSMIC.
In summary, our analysis shows that treatment of SI-
NET cells with the neddylation inhibitor pevonedistat
results in a rapid stabilization of CRL targets, including
well-known tumor suppressors such as p27.
Pevonedistat treatment of NET cells results in
increased p27 level and induction of apoptosis
To further investigate the effects of pevonedistat treatment
in NET cells, CNDT2, HC45, BON-1, and NCI-H727 cells
were treated for 72 h with pevonedistat in increasing con-
centrations from 100 to 1600 nM. Western blotting analysis
of protein neddylation using anti-NEDD8 antibody revealed
the reduction of a band (~90 kDa) corresponding to the
predicted size of Cullin conjugated with NEDD8 in all cell
lines (Fig. 5a). The expression level of unconjugated
NEDD8 at 9 kDa as well as unconjugated Cullin-1 did not
demonstrate a difference between untreated and treated cells
at different concentrations. This result is in line with pre-
vious literature showing inhibition of Cullin neddylation as
an important effect of pevonedistat treatment [20]. Further,
western blotting analysis of p27 confirmed the results from
the proteomics analysis as increased level of p27 was
observed in all cell lines in a dose-dependent manner.
The BrdU incorporation assay clearly showed that treat-
ment with pevonedistat results in reduced proliferation (Fig.
2a and Supplementary Fig. S2). To evaluate induction of
apoptosis in response to pevonedistat, poly(ADP-ribose)
polymerase (PARP) cleavage was assayed using Western
blot. In three out of four NET cell lines, a dose-dependent
increase in cleaved PARP (cPARP) was detected (Fig. 5a). To
further confirm the induction of apoptosis in response to
pevonedistat treatment in NET cells, Annexin V staining was
assessed by flow cytometry. After 3 days of pevonedistat
treatment, the proportion of cells that were stained by
Annexin V was increased in all cell lines, indicating the
induction of apoptosis (Fig. 5b). Collectively, these results
show that inhibition of neddylation using pevonedistat treat-
ment results in a dose-dependent stabilization of p27 as well
as induction of apoptosis in all NET cell lines examined.
p27 stability is dependent on NEDD8 and RBX1
levels
According to our hypothesis, altered levels of NEDD8 and
RBX1 could contribute to altered CRL activity and conse-
quently also to altered stability of CRL substrates such as p27.
To investigate this further, we used small interfering RNA
(siRNA)-based silencing to monitor the effects of knocking
down NEDD8 and RBX1 in CNDT2 cells. Importantly,
silencing of either NEDD8 (Fig. 6a) or RBX1 (Fig. 6b)
resulted in a clear increase in p27 protein levels, strongly
indicating that either one of these proteins are rate limiting for
the CRL activity and the degradation of CRL substrates.
As shown above, many different substrates are affected
by CRL inhibition using pevonedistat in SI-NET cells. To
investigate the relative contribution of p27 to the effects of
pevonedistat, we used siRNA-based silencing of p27 in a
rescue experiment. p27 is efficiently degraded via the pro-
teasome and, therefore, knockdown efficiency was eval-
uated in pevonedistat-treated CNDT2 cells (Fig. 6c). As a
readout of pevonedistat effect, Annexin V staining was
assessed by flow cytometry to evaluate early apoptotic
events 24 h after treatment (Fig. 6c, Supplementary Fig S4,
and Supplementary Table S9). This experiment showed that
silencing of p27 using two different siRNAs resulted in a
partial rescue of pevonedistat effects as indicated by a
decrease in early apoptotic cells (AnnV+/PI−) and an
increase in healthy cells (AnnV−/PI−).
Further, similar to what was seen after inhibition of CRL
activity using pevonedistat, silencing of NEDD8 and RBX1
resulted in induction of apoptosis as indicated by increased
PARP cleavage (Fig. 6d). Part of this effect was dependent
on p27, as we noted a clear reduction of PARP cleavage
after silencing of p27.
In conclusion, these experiments show a causal link
between cellular NEDD8 or RBX1 levels and p27 levels,
and that the cellular effects of CRL inhibition using pevo-
nedistat or NEDD8/RBX1 silencing is in part dependent on
stabilization of p27.
Fig. 3 Proteomics profiling of response to pevonedistat in SI-NET cell
lines. a Scatterplots showing the results from the quantitative pro-
teomics experiments of pevonedistat in CNDT2 cells (left) and HC45
cells (right) at four different time points each. Plotted values represent
log2 ratio between the indicated sample and average of untreated
duplicate samples. Red lines indicate the cutoffs for regulation as
defined in Supplementary Fig. 2. In each scatterplot, the number of
proteins regulated in both cell lines are indicated as well as the overall
correlation between replicate A and B. b Venn diagram showing the
overlap between CNDT2 and HC45 in proteins upregulated 24 h after
pevonedistat treatment. c Heatmap showing proteins detected as
upregulated at 24 h in both CNDT2 and HC45. Indicated in the
heatmap are examples of CRL substrates that are stabilized in response
to pevonedistat treatment. d Overlap analysis between proteins iden-
tified as stabilized after pevonedistat treatment in SI-NET cells and
previously identified CRL substrate candidates. e Overlap analysis
between pevonedistat-stabilized proteins in SI-NET cells and in
oncogenes/tumor suppressor genes (TSG) according to COSMIC
Cancer Gene Census. f Overlap analysis between pevonedistat-
stabilized proteins in SI-NET and proteins quantified in SI-NET
clinical samples (top). Bottom plot shows a correlation analysis in
clinical samples between pevonedistat-stabilized proteins and NEDD8
based on clinical proteomics data. The x-axis indicate the rank of
stabilized proteins in relation to all proteins the SI-NET clinical dataset
(n= 6775) with respect to the NEDD8 correlation
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Fig. 4 CRL substrate evaluation by proteomics profiling of bortezomib
effects in CNDT2 SI-NET cells. a Venn diagram showing identifica-
tion overlap in CNDT2 cells between proteomics profiling of pevo-
nedistat effects (as described in Fig. 3) and bortezomib effects (top),
and scatterplot indicating proteins found to be stabilized by mono-
therapy with pevonedistat and/or bortezomib (bottom). b Vulcano plot
showing protein-level regulation in response to bortezomib treatment
of CNDT2 cells. Indicated in the plot are proteins also found to be
stabilized by pevonedistat treatment in CNDT2 cells (blue) or both
CNDT2 cells and HC45 cells (red) as described in Fig. 3. c Scatterplot
showing CNDT2 cells’ protein-level regulation in response to borte-
zomib treatment alone or in combination with pevonedistat. Dashed
line indicate 99th percentile of the comparison between effects after
treatment with bortezomib/pevonedistat combination and bortezomib
alone. Pink area indicate proteins that are stabilized to a higher degree
after combination treatment. d Western blotting showing p27 levels in
response to treatment of CNDT2 cells with bortezomib and pevone-
distat alone or in combination. The barplot indicates relative protein
levels normalized to GAPDH. Western blotting quantification was
based on three independent experiments with barplot error bars indi-
cating SD and p-values calculated by Student’s t-test. e Barplot
showing the 30 SI-NET CRL substrate candidates that were stabilized
more in response to bortezomib pevonedistat combination than bor-
tezomib alone in CNDT2 cells. Indicated in green are proteins defined
as tumor suppressors (TSG) in COSMIC
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Clinical evaluation of CDKN1B/p27 and NEDD8 in SI-
NET
Next, we evaluated the connection between CDKN1B/p27
and NEDD8 in two other SI-NET clinical sample cohorts.
In the first cohort (Supplementary Table S10), the mRNA
level relationship between CDKN1B and NEDD8 was
assessed in 62 SI-NET samples from 47 patients using
quantitative real-time PCR (qPCR). Supporting the MS-
based protein level analysis, a positive correlation was here
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observed between CDKN1B and NEDD8 mRNA levels
(Supplementary Fig. S5). This result suggests that there
could be a transcriptional feedback mechanism between
CDKN1B and NEDD8. To investigate potential causes of
differential CDKN1B expression in SI-NET, we investi-
gated CDKN1B copy number alterations and CDKN1B
promoter methylation. Eight tumors showed copy number
loss of CDKN1B, two tumors had copy number gain,
whereas the remaining tumors exhibited two copies. How-
ever, no significant association could be found between
CDKN1B expression and copy number alterations.
CDKN1B promoter methylation was quantified by Pyr-
osequencing. Low levels of methylation with MetI below
10% were revealed in 64/65 tumor samples, whereas one
single case had an increased MetI of 26% (Supplementary
Table S10). In summary, the differential mRNA expression
of CDKN1B in SI-NET could not be explained by altered
copy number or promotor methylation.
To evaluate protein-level association between NEDD8
and p27, immunohistochemistry (IHC) analysis was
employed in a separate cohort of 43 SI-NETs (Supple-
mentary Table S11). NEDD8 and p27 demonstrated a
spectrum of none to high cytoplasmic and nuclear staining
intensities among different samples (Fig. 7a–d). However,
no association between the level of NEDD8 and p27 or with
clinicopathological features including presence of liver
metastasis was observed. In summary, these results did not
validate the initial finding that NEDD8 protein levels were
directly coupled to the presence of liver metastasis. The
immunohistochemical analysis however did support the
differential expression of both NEDD8 and CDKN1B/p27
in SI-NET, indicating that some tumors may be relying on
increased CRL activity for growth and survival.
Discussion
The proteomics profiling here performed indicates over-
expression of the CRL regulators NEDD8 and RBX1 in a
subset of SI-NETs. Further, the strong correlation between
NEDD8 and RBX1 both at protein level, as detected in SI-
NET, and at mRNA level shown by public domain data
analysis across different cancer types suggest that these
genes are transcriptionally co-regulated. Previous research
support a connection between overexpression of these two
proteins and cancer. As an example it has been shown that
high expression of RBX1 is coupled to poor prognosis in
gastric cancer [25], bladder cancer [26], and non-small cell
lung cancer [27]. Similarly, NEDD8 overexpression has
been coupled to poor prognosis in hepatocellular carcinoma
[28] and bladder cancer [29], and increased levels of ned-
dylated Cullin-1 has previously been shown in high-grade
lung NETs [30]. Also in nasopharyngeal carcinoma, over-
expression of NEDD8 was coupled to shorter overall sur-
vival [31] and in the same publication it was also shown in
cell line models that suppression of NEDD8 levels directly
inhibits cell growth. In addition, enzymes involved in the
neddylation process are upregulated in a range of different
cancer types [32].
Previous studies have shown that CDKN1B stands out so
far as the only recurrently mutated gene in SI-NETs,
establishing CDKN1B/p27 as a key tumor suppressor in this
disease [6]. The relatively low frequency of CDKN1B
mutations (<10%) however suggests that additional, so far
unknown, mechanisms to inactivate tumor suppressors exist
in SI-NET. The data presented here show considerable
heterogeneity between individual SI-NETs in expression of
CDKN1B/p27, both at the mRNA and at the protein level.
At the mRNA level, these differences could not be directly
attributed to copy number differences or epigenetic reg-
ulation by methylation. This would suggest that other
mechanisms such as transcriptional and posttranscriptional
regulation affect the mRNA level of CDKN1B in SI-NET.
Intriguingly, we did detect an association between the
mRNA level of CDKN1B and the mRNA level of NEDD8
in SI-NET. This finding could indicate that a negative
feedback mechanism exists at the transcriptional level to
limit the inhibitory effect of p27 on cell cycle entry.
Importantly, inhibition of neddylation resulted in stabiliza-
tion of p27 in all four NET cell lines examined, clearly
showing that p27 levels are controlled at the posttransla-
tional level in NET. Further, silencing of either NEDD8 or
RBX1 resulted in stabilization of p27, indicating that the
level of these proteins directly impacts on CRL activity and
stability of substrates such as p27. Our data thus suggest
that in a subgroup of SI-NETs, an additional mechanism to
overcome the tumor suppressor function of CDKN1B/p27
could be through increased CRL activity resulting in
Fig. 6 p27 stability is dependent on NEDD8 and RBX1 levels. a
Western blotting showing NEDD8 and p27 levels in response to
siRNA-based silencing of NEDD8 in CNDT2 cells. The barplot
indicates relative protein levels normalized to GAPDH as determined
by densitometry analysis of western blotting results. b Western blot-
ting and barplot showing RBX1 and p27 levels in response to siRNA-
based silencing of RBX1 in CNDT2 cells. c Western blotting and
barplot showing p27 levels in response to siRNA-based silencing of
p27 in CNDT2 cells (left). Right barplot shows flow cytometry ana-
lysis of Annexin V and PI staining of CNDT2 cells for evaluation of
early apoptosis in response to pevonedistat. Colors indicate whether
cells were pretreated with siRNA for silencing of p27 (pink or red) or
non-targeting control siRNA (green). Error bars in flow cytometry
analysis indicate SEM from six experiments, and p-values were cal-
culated using paired t-test. d Western blottings and barplot showing
p27, NEDD8, RBX1, and cleaved PARP (cPARP) levels in response
to siRNA-based silencing of NEDD8/RBX1 in combination or
NEDD8/RBX1/p27 in combination in CNDT2 cells. NTC lane in
western blotting indicate non-transfected control cells (NTC). All
western blotting quantifications were based on three independent
experiments with barplot error bars indicating SD and p-values cal-
culated by Student’s t-test
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degradation of p27. Deregulation of CDKN1B/p27 has been
reported in many cancer types [33, 34], but mutations are
rare and loss of heterozygosity with total loss of expression
is not observed in cancer [35]. Several studies have shown
that complete loss of p27 would result in abrogation of cell
proliferation, whereas expression levels lower than normal
can lead to increased cyclin-dependent kinase activity and
subsequent cell proliferation [36, 37]. Based on the recur-
rent heterozygous inactivating mutations in SI-NET,
CDKN1B is considered a haploinsufficient tumor sup-
pressor gene. In other words, the expression of CDKN1B
from a single copy is insufficient to sustain a tumor sup-
pressor function. A similar net effect could be accomplished
in non-mutated tumors by increasing the proteasomal
degradation of p27 through activation of CRLs.
Even though we were unable to establish a direct rela-
tionship between NEDD8 expression and SI-NET progres-
sion or metastasis, our data point out inhibition of
neddylation as a potential therapeutic strategy in a subset of
SI-NETs. In patients with tumors showing reduced level of
p27, either through heterozygous mutations or through
augmented proteasomal degradation, increasing the levels
of p27 through inhibition of its degradation could prove to
be a successful treatment strategy.
Targeting the neddylation pathway as a therapeutic strat-
egy for cancer treatment was first demonstrated by the
development of the NAE inhibitor pevonedistat [20]. Pevo-
nedistat was shown to inhibit cullin neddylation, resulting in a
concomitant stabilization of a number of known CRL sub-
strates including p27, Nrf2, and CDT1, loss of cell cycle
control, and induction of apoptosis. It was speculated that the
specific cell death mechanism was at least in part due to
CDT1-stimulated re-replication without cell cycle progres-
sion, ultimately triggering apoptosis. As all cullins are ned-
dylated by NAE, it is expected that all CRL complexes would
be inhibited by pevonedistat, whereas other, non-CRL E3
ligases, would remain active. It was estimated by a protein
turnover analysis comparing bortezomib with pevonedistat
that ~20% of the proteasome-dependent degradation is
mediated by CRL-dependent ubiquitination [20]. The mole-
cular mechanism of action for pevonedistat was later descri-
bed, as it was shown that in the presence of pevonedistat,
NAE catalyzes the formation of a NEDD8-pevonedistat
adduct. The stability of this adduct within the active site of
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Fig. 7 Clinical evaluation of
NEDD8 and CDKN1B/p27. a
Overview of
immunohistochemistry analysis
for NEDD8 and p27 in 43
primary SI-NETs is shown. b–d
Photomicrographs exemplifying
diverse cytoplasmic and nuclear
intensity of NEDD8 and p27
immunoreactivity in SI-NETs. b
Case IHC-7 demonstrating
strong cytoplasmic and nuclear
NEDD8 (3+) and weak
cytoplasmic and nuclear p27
(1+) staining, respectively. c
Case IHC-18 exhibiting weak
NEDD8 (1+) and strong p27
immunoreactivity. d Case IHC-5
with strong staining (3+) for
both proteins. Cytoplasmic and
nuclear staining were intimately
associated and therefore scored
conjoined. Membranous staining
patterns were not observed. All
photomicrographs are magnified
×100
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NAE effectively and specifically blocks further NAE enzy-
matic activity [38]. Pevonedistat has recently been evaluated
in phase I trials for treatment of different cancer types such as
myeloma/lymphoma [39], AML [40], melanoma [41], and
other solid tumors [42], in all instances showing that pevo-
nedistat in general was well tolerated at doses tested. To our
knowledge, this is the first report describing the use of
pevonedistat in neuroendocrine cells. Importantly, we show
here that SI-NET cell lines are sensitive to CRL inhibition by
both NEDD8/RBX1 silencing and pharmacological inhibition
of the neddylation machinery using pevonedistat. Our data
also show that part of the cellular effects of CRL inhibition is
p27 dependent, as silencing of p27 resulted in reduced
apoptosis.
Further, proteomics time-course profiling of pevonedistat
effects in two different SI-NET cell lines revealed rapid sta-
bilization of multiple proteins, in line with the anticipated
effects of CRL inhibition. Additional proteomics profiling of
cellular response to proteasomal inhibition using bortezomib
allowed us to nominate a short list of candidate CRL sub-
strates in SI-NET. Among the stabilized proteins were several
well-known CRL substrates as well as canonical tumor sup-
pressors with potential importance in SI-NET. Even though
we have focused our attention to p27 as an important CRL
target in SI-NET, our analysis identified additional proteins
that were stabilized in response to pevonedistat. Anyone of
these proteins or a cohort of them could contribute to the
effects of pevonedistat treatment in SI-NET. These results
could prove important in the future work to identify predictive
markers for pevonedistat treatment.
In summary, our study supports the significance of the
CDKN1B/p27 in SI-NET and identifies CRL-dependent
proteasomal degradation as an additional mechanisms for
inactivation of this tumor suppressor in SI-NET. Based on
this finding we evaluated and showed neddylation as a
potential new drug target in SI-NET cells using the targeted
compound pevonedistat. Future studies are needed to
evaluate the use of pevonedistat in a clinical setting as well
as to identify predictive biomarkers in SI-NET.
Materials and methods
Cell lines
Four NET cell lines were used (BON-1, NCI-727, HC45,
and CNDT2). Sources, verifications, and culturing condi-
tions are given in Supplementary Methods.
Tissue samples
All tissue samples were obtained from the Karolinska
University Hospital biobank and had been collected with
informed patients’ consent and approval from the local
ethics committee in Stockholm (Dnr:2012/305-31/1).
Fourteen tumors (Screen-1 to -14; Supplementary Table S1)
were used for proteomics. Another 70 tumors (case numbers
1–70; Supplementary Table S10) from 50 SI-NET patients
were used for pyrosequencing and qPCR analyses. An
additional cohort of 43 paraffin-embedded tumors (IHC-1 to
-43; Supplementary Table S11) was used for IHC. Adjacent
normal tissues from 12 patients served as non-tumor refer-
ences. Further descriptions are given in Supplementary
Methods.
Proteomics analysis using HiRIEF-LC-MS/MS
Protein expression profiles were generated using the
HiRIEF-LC-MS/MS methodology [43] and procedures
detailed in refs. [44] and [45]. In the first proteomics
analysis, primary SI-NETs from seven patients with liver
metastases and from seven patients without detectable
liver metastases at the time of surgery were included. In
the second proteomics analysis, CNDT2 and HC45 cells
treated with 400 nM pevonedistat for 3, 6, 12, or 24 h as
well as dimethylsulfoxide (DMSO)-treated control cells
were analyzed in duplicates. In the third proteomics ana-
lysis, CNDT2 cells treated with 500 nM bortezomib (tri-
plicate), 500 nM bortezomib plus 500 nM pevonedistat
(triplicate) for 12 h, as well as DMSO-treated control cells
(four replicates) were analyzed. The MS proteomics data
have been deposited to the ProteomeXchange Consortium
via the PRIDE partner repository with the dataset identi-
fier PXD009877 and PXD013024. Experimental proce-
dures and data analyses are further described in
Supplementary Methods.
Proliferation assay
For the proliferation assay, BrdU proliferation kit
(Roche) was used following the manufacturer’s instruc-
tions. Briefly, cells were seeded in 96-well plates and
treated with pevonedistat at concentration 0, 100, 200,
400, 600, 800, 1000, and 2000 nM for 3 days. BrdU
reagent was added to the medium for a period of 4 h after
which cells were fixed and incubated with the BrdU
antibody for 90 min. The intensity of the colorimetric
reaction, which is proportional to the incorporated BrdU,
was measured at the wavelength 370 nm and the reference
wavelength of 492 nm using a microplate ELISA reader
(VERSAmax; Molecular Devices, Sunnyvale, CA, USA).
Curve fitting and generation of dose–response figures was
performed in R using the drc package [46] with standard
settings using the four-parameter log-logistic model
function (LL.4). IC50 values were then retrieved from the
fitted curve.
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Flow cytometry assessment of apoptosis
Apoptosis assays were performed based on redistribution of
phosphatidylserine phospholipid components of the cell
membrane and a high affinity of Annexin V fluorescein
(FLUOS) toward phosphatidylserine. BON-1, CNDT2,
HC45, and NCI-H727 cells were treated with DMSO as a
control or pevonedistat at the concentrations of 500 and
1000 nM in three wells of a six-well plate for 3 days. After
collection of cells by trypsination and washing twice in cold
phosphate-buffered saline, cells were incubated for 15 min
in fluorescence-activated cell sorting (FACS) buffer
(10 mM HEPES/NaOH pH 7.4, 140 mM NaCl, 5 mM
CaCl2) containing 20 µl Annexin V and 20 µl propidium
iodide (50 µM) added per ml buffer. Thereafter, 400 µL of
FACS buffer was added to the cells and analysis was per-
formed using NovoCyte flow cytometer (ACEA Bios-
ciences, San Diego, CA, USA) following the
manufacturer’s instructions (Roche 11828681001). For the
analysis of four different NET cell lines, the mean of data
from at least three independent biological replications were
used to create the graphs (Fig. 4b). For the siRNA experi-
ment, CNDT2 cells were first transfected with either an
siRNA targeting p27 or a negative control siRNA. Twenty-
four hours after transfection, cells were treated with either
DMSO or 500 nM pevonedistat for 24 h before analysis.
Staining was carried out as described above and the FACS
analysis was carried out on a Fortessa flow cytometer (BD
Biosciences, San Jose, CA, USA). The mean of the data
from at least six independent experiments was used to create
the graphs.
siRNA-based silencing
siRNA treatments of CNDT2 cells were performed
according to standard protocol. Briefly, RNAiMAX
transfection reagent (Invitrogen) and siRNA (two siRNA
each for RBX1, NEDD8, CDKN1B, and negative control;
Qiagen) were diluted separately in Opti-MEM medium
(ThermoFisher), mixed (1:1 ratio), and incubated for
5 min. RNA-lipid complexes were then added to cells in
six-well plates, seeded to be 60% confluent at transfec-
tion, and cells were then incubated for 1–3 days at 37 °C
before analysis.
Western blotting analyses
Proteins were extracted from the cell lines, separated by
SDS-polyacrylamide gel electrophoresis and transferred to
nitrocellulose or polyvinylidene difluoride membranes
(Invitrogen). After blocking in albumin or milk, membranes
were incubated at 4 °C overnight with primary antibodies
for NEDD8 (19E3, Cell Signaling) at dilution 1:1000,
RBX1 (D3J5I, Cell Signaling) at 1:1000, cPARP (E51,
Abcam) at 1:10,000, p27 (D69C12, Cell Signaling) at
1:1000, p27 (sc-528, Santa Cruz) at 1:500, Cullin 1 (Santa
Cruz 1:1000), and GAPDH (sc-47724, Santa Cruz) at
1:10,000). GAPDH was used as a control of loading and
transfer. Each experiment was biologically repeated at least
three times.
DNA copy number, gene expression, and
methylation analyses
DNA copy numbers were determined by qPCR for
CDKN1B (Hs02134847_cn, Applied Biosystems) and the
endogenous control RNaseP (#4403326, ThermoFisher
Scientific) according to the methodology described in ref.
[47]. Gene expressions were quantified by TaqMan for
CDKN1B (Hs01597588_m1, Applied Biosystems) and
NEDD8 (Hs04187792_m1) with the endogenous control
ACTB (Hs99999903_m1). DNA methylation was quantified
for the CDKN1B promoter (Hs_CDKN1B_01_PM, Qiagen)
using pyrosequencing. For further details and experimental
procedures, see Supplementary Methods.
Immunohistochemistry
IHC was performed on the 43 SI-NET tissue samples for
NEDD8 (Cell Signaling) and p27 (Cell Signaling, D69C12)
as detailed in Supplementary Methods. A combined score of
nuclear and cytoplasmic staining was obtained: 0 (absent), 1
(low), 2 (medium), and 3 (high).
Statistical analyses
Statistical comparisons were done using Student’s t-test,
Fisher’s exact test, Mann–Whitney U-test, Pearson’s or
Spearman’s correlation. Details are given in Supplementary
Methods.
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